{"schema_version":1,"assessment_id":"eoa_inverse_innovation_exp03_opportunity320_20260801","source_experiment_id":"eoa_inverse_innovation_exp03_full320_20260801","cell_id":"invariant_mode_decomposition_design__pharmacology_toxicology","archetype_slug":"invariant_mode_decomposition_design","domain_slug":"pharmacology_toxicology","title":"Harm-weighted transition-mode analysis for coupled repeat-dose toxicity signals","opportunity_summary":"Retrospectively estimate and validate joint longitudinal toxicity modes that may reveal persistent or growing, biologically consequential trajectories before individual biomarkers cross alert thresholds. The proposal is structurally testable and safety-governed, but demand, prevalence, performance, and distinctiveness from existing multivariate methods remain unverified.","adopter_authorizer":"A toxicology study director could authorize decision-neutral shadow analysis. Any prospective exposure, sampling, or protocol change would additionally require the protocol owner, veterinarian, animal-welfare body, and organizational safety governance.","scores":{"meaningful_impact":{"score":4,"rationale":"If coupled subthreshold trajectories materially precede overt injury, earlier detection could improve safety-margin estimation, monitoring, and dose selection for study animals and downstream participants. The frequency and magnitude of such missed trajectories are unsupported."},"stakeholder_pull":{"score":2,"rationale":"The candidate identifies toxicologists, study directors, sponsors, regulators, and welfare authorities as affected stakeholders, but provides no evidence that they currently prioritize, procure, or request this capability or that the stated failure is prevalent."},"incremental_advantage":{"score":3,"rationale":"The proposed modes, stability checks, spectral-gap gates, and harm weighting offer a testable difference from coordinate-wise review and direct-outcome predictors. Whether they improve detection timing or false-alert performance is wholly hypothetical."},"distinctiveness_plausibility":{"score":3,"rationale":"The composition of invariant transition modes, harm-weighted sensitivity, and explicit spectral validity gates is plausibly differentiated, but prior art is unsearched and overlap with longitudinal multivariate, state-space, PK/PD, or toxicity-prediction methods is unknown."},"technical_implementability":{"score":3,"rationale":"A decision-neutral retrospective analysis on a completed study is technically bounded, but small samples, missingness, scaling, correlated error, nonlinear biology, non-normal transients, poor conditioning, and mode instability could make the decomposition unusable."},"adoption_authority_feasibility":{"score":4,"rationale":"The candidate names a study director who can authorize shadow analysis and separately identifies the authorities required for prospective changes. Feasibility is reduced by the need for compound-specific validation and multi-party approval before operational influence."},"evidence_readiness":{"score":3,"rationale":"The packet supplies a preregisterable held-out comparison, outcomes, falsifiers, and halt criteria, making a first test well specified. It does not establish that a suitable completed dataset, adequate sample size, measurement quality, or independent replicate is available."},"safety_net_benefit":{"score":4,"rationale":"The approach targets earlier recognition of otherwise missed toxicity while retaining ordinary review, prohibiting model-only exposure changes, and specifying rollback for unstable or excessive-alert models. False reassurance and compression of rare signals remain material hazards."},"scalability":{"score":2,"rationale":"The analytic pattern could be reused, but the candidate explicitly requires revalidation across compounds, populations, and settings; heterogeneous sampling, biomarker panels, scaling, and changing biology may prevent stable transfer."}},"score_confidence":"MODERATE","costs":{"first_evidence":{"band_2026_usd":"50K_TO_250K","scope":"One preregistered, decision-neutral shadow analysis of a completed repeat-dose study, including data preparation, toxicology and statistical labor, baseline and rival comparisons, blinded held-out evaluation, and reporting.","confidence":"MODERATE","assumptions":["An appropriate completed study and necessary measurements already exist and are accessible.","No new animals, samples, assays, or prospective protocol changes are required.","The analysis requires specialist toxicology, longitudinal modeling, and independent evaluation effort.","Data cleaning and governance are substantial but confined to one study."]},"initial_deployment_startup":{"band_2026_usd":"250K_TO_1M","scope":"Prepare a validated decision-support capability for a limited organizational program, including data integration, reproducible software, access controls, model validation, SOPs, governance review, training, and compound-specific configuration.","confidence":"LOW","assumptions":["Retrospective evidence has passed preregistered criteria.","Deployment remains advisory and does not autonomously change exposure or sampling.","Existing laboratory and study-data systems can be integrated without wholesale replacement.","The scope is one organization and a limited set of studies rather than enterprise-wide rollout."]},"operational_launch":{"band_2026_usd":"250K_TO_1M","scope":"Launch a governed, limited prospective evaluation with parallel ordinary review, monitoring, confirmatory analysis, welfare oversight, and formal comparison against the nearest rival.","confidence":"LOW","assumptions":["Required protocol, veterinarian, welfare, and safety-governance approvals are obtainable.","No major new laboratory equipment or large animal-study expansion is required.","Prospective use initially remains bounded and closely supervised.","Independent validation and incident-response capacity are included."]},"annual_recurring":{"band_2026_usd":"250K_TO_1M","scope":"Operate the capability across a limited toxicology program, including specialist review, data operations, software maintenance, drift and conditioning monitoring, audit support, and repeated study- or compound-level revalidation.","confidence":"LOW","assumptions":["Each materially different compound, regimen, population, or measurement panel requires revalidation.","Ordinary toxicology review remains in place rather than being replaced.","Recurring costs depend strongly on study volume and data standardization.","The estimate excludes major new animal studies undertaken solely for this method."]}},"research_burden":"HIGH","earliest_credible_horizon":"3_TO_12_MONTHS","pipeline_gates":{"recognizable_externally_supportable_problem":{"status":"UNCERTAIN","reason":"The candidate clearly states a falsifiable coupled, subthreshold toxicity-detection problem, but supplies no external evidence of its prevalence, severity, or recurrence in actual repeat-dose programs."},"identifiable_adopter_or_authorizer":{"status":"YES","reason":"The toxicology study director is identified as the shadow-analysis authorizer, with protocol, veterinary, animal-welfare, and organizational governance named for prospective changes."},"distinct_testable_incremental_claim":{"status":"YES","reason":"The proposal can be tested for earlier held-out detection and acceptable false alerts relative to coordinate-wise review and a supervised multivariate or conventional PK/PD rival, with modal stability and residual criteria."},"bounded_next_evidence_step":{"status":"YES","reason":"A preregistered shadow analysis on one completed study is bounded, decision-neutral, blinded on held-out observations, and includes explicit comparisons and failure conditions."},"no_unresolved_safety_or_authority_stop":{"status":"YES","reason":"The first step changes no decisions, preserves ordinary review, names required authorities for later changes, excludes model-only interventions, and specifies halt and rollback conditions."},"implementation_cost_scope_and_range":{"status":"YES","reason":"The first analysis and limited deployment stages can be scoped separately and assigned broad resource-equivalent bands, although data condition, study volume, and integration complexity keep later estimates uncertain."}},"blocking_evidence":["No external evidence establishes how often coordinate-wise review misses consequential coupled toxicity trajectories.","No empirical result shows that reproducible, well-conditioned, spectrally separated risk modes exist in suitable repeat-dose data.","No held-out comparison demonstrates earlier or more accurate detection than ordinary review or the nearest multivariate rival.","Prior art is unsearched, so the proposed composition's distinctiveness is unresolved.","Availability and adequacy of a completed dataset with sufficient longitudinal observations, endpoints, and replicate structure are not established.","No prospective evidence shows that mode-ranked assays or governed intervention hypotheses improve detection, prediction, or control."],"next_evidence_step":"Conduct the authorized preregistered shadow analysis on one completed repeat-dose study: fit only on designated animals and early time points, then compare blinded held-out detection timing and false alerts against coordinate-wise review and a prespecified supervised multivariate or PK/PD rival. Falsify advancement if univariate review is at least as early and accurate, no repeatable coupled signal remains after exposure, time, and measurement error are addressed, or conditioning, modal identity, spectral separation, drift, or harm-weighted residuals fail their preregistered limits.","research_questions":["How often do consequential toxicities exhibit coupled subthreshold dynamics before ordinary review produces an alert?","Are estimated modes reproducible across blinded animals, time windows, analytical choices, and replicate studies?","Do mode-based signals improve detection timing or accuracy without exceeding the baseline false-alert tolerance?","How sensitive are results to scaling, missingness, correlated measurement error, sparse sampling, nonlinearity, and non-normal transient amplification?","Does the full proposal materially differ from existing longitudinal multivariate toxicology, state-space safety, PK/PD, and supervised prediction methods?","Can harm weights and residual budgets be specified prospectively without encoding unsupported biological interpretations?","Do mode-ranked confirmatory assays or governed dose, schedule, and monitoring hypotheses outperform the nearest rival in a later bounded test?","What study characteristics determine when compound- or setting-specific revalidation is required?"] ,"recommendation":"PRIOR_ART_RESEARCH","uncertainty_constraints":["Closed-book assessment; no external sources were consulted.","Problem prevalence, stakeholder demand, market size, realized impact, and adoption appetite are unmeasured.","Prior-art status is explicitly unsearched, so world novelty and practical distinctiveness cannot be scored as established.","Performance, reproducibility, thresholds, and biological interpretations are hypotheses rather than demonstrated results.","Cost bands are resource-equivalent ranges based on stated scope, not observed quotations or point estimates.","The candidate does not confirm access to a sufficiently powered, well-curated completed study.","Mathematical modes must not be interpreted as separable biological mechanisms or independently controllable processes.","Results cannot transfer to another compound, regimen, population, or clinical setting without revalidation."],"closed_book_prior_art_boundary":"The sealed packet supports only the possibility that combining transition-mode decomposition, harm-weighted sensitivity, modal stability, spectral-gap failure gates, and governed toxicology use is structurally distinctive. It provides no literature, product, patent, practice, or adoption evidence and therefore cannot establish novelty or separation from existing longitudinal multivariate toxicology, state-space, PK/PD, or safety-prediction approaches."}